We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In an April 6, 2012, filing with the U.S. Securities and Exchange Commission, Israel-based PROLOR Biotech, Inc. has registered the sale of common stock on the American Stock Exchange in an amount not to exceed $75 million
